company background image

9 Meters Biopharma NasdaqCM:NMTR Stock Report

Last Price


Market Cap







04 Oct, 2022


Company Financials +
NMTR fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

NMTR Stock Overview

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders.

9 Meters Biopharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for 9 Meters Biopharma
Historical stock prices
Current Share PriceUS$0.23
52 Week HighUS$1.43
52 Week LowUS$0.20
1 Month Change-11.29%
3 Month Change6.58%
1 Year Change-81.92%
3 Year Change-77.40%
5 Year Changen/a
Change since IPO-95.95%

Recent News & Updates

Aug 15

9 Meters Biopharma GAAP EPS of -$0.04 in-line

9 Meters Biopharma press release (NASDAQ:NMTR): Q2 GAAP EPS of -$0.04 in-line. As of June 30, 2022, the company's cash and cash equivalents totaled approximately $29.5M, compared to approximately $37.2M as of March 31, 2022.

Shareholder Returns

NMTRUS PharmaceuticalsUS Market

Return vs Industry: NMTR underperformed the US Pharmaceuticals industry which returned 4.4% over the past year.

Return vs Market: NMTR underperformed the US Market which returned -20% over the past year.

Price Volatility

Is NMTR's price volatile compared to industry and market?
NMTR volatility
NMTR Average Weekly Movement11.2%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: NMTR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: NMTR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

n/a21John Temperato

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications.

9 Meters Biopharma Fundamentals Summary

How do 9 Meters Biopharma's earnings and revenue compare to its market cap?
NMTR fundamental statistics
Market CapUS$60.89m
Earnings (TTM)-US$45.58m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NMTR income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$45.58m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.18
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NMTR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is NMTR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NMTR?

Other financial metrics that can be useful for relative valuation.

NMTR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does NMTR's PB Ratio compare to its peers?

NMTR PB Ratio vs Peers
The above table shows the PB ratio for NMTR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average11.9x
LVCE LiveCare
SHWZ Medicine Man Technologies
OPNT Opiant Pharmaceuticals
ETON Eton Pharmaceuticals
NMTR 9 Meters Biopharma

Price-To-Book vs Peers: NMTR is good value based on its Price-To-Book Ratio (2.8x) compared to the peer average (11.9x).

Price to Earnings Ratio vs Industry

How does NMTR's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: NMTR is expensive based on its Price-To-Book Ratio (2.8x) compared to the US Pharmaceuticals industry average (1.7x)

Price to Book Ratio vs Fair Ratio

What is NMTR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NMTR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NMTR's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of NMTR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NMTR ($0.24) is trading below our estimate of fair value ($42.73)

Significantly Below Fair Value: NMTR is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is 9 Meters Biopharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NMTR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NMTR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NMTR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NMTR is forecast to have no revenue next year.

High Growth Revenue: NMTR is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NMTR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has 9 Meters Biopharma performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NMTR is currently unprofitable.

Growing Profit Margin: NMTR is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: NMTR is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.

Accelerating Growth: Unable to compare NMTR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NMTR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).

Return on Equity

High ROE: NMTR has a negative Return on Equity (-206.37%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is 9 Meters Biopharma's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NMTR's short term assets ($31.3M) exceed its short term liabilities ($9.3M).

Long Term Liabilities: NMTR's short term assets ($31.3M) exceed its long term liabilities ($83.2K).

Debt to Equity History and Analysis

Debt Level: NMTR is debt free.

Reducing Debt: NMTR currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NMTR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NMTR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.4% each year

Discover healthy companies


What is 9 Meters Biopharma current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

9 Meters Biopharma Dividend Yield vs Market
How does 9 Meters Biopharma dividend yield compare to the market?
SegmentDividend Yield
Company (9 Meters Biopharma)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.5%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (9 Meters Biopharma)n/a

Notable Dividend: Unable to evaluate NMTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NMTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NMTR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NMTR's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NMTR has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


John Temperato (57 yo)





Mr. John Temperato has been President, Chief Executive Officer and Director at 9 Meters Biopharma Inc. (formerly known as 9 Meters Biopharma, Inc.) since April 30, 2020. Mr. Temperato served as Chief Execu...

CEO Compensation Analysis

John Temperato's Compensation vs 9 Meters Biopharma Earnings
How has John Temperato's remuneration changed compared to 9 Meters Biopharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$2mUS$537k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$2mUS$329k


Compensation vs Market: John's total compensation ($USD2.19M) is above average for companies of similar size in the US market ($USD772.75K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: NMTR's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Experienced Board: NMTR's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: NMTR insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

NasdaqCM:NMTR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Jul 22BuyUS$28,463John TemperatoIndividual125,000US$0.23
01 Jul 22SellUS$912,662OrbiMed Advisors LLCCompany2,995,601US$0.56
23 May 22BuyUS$7,608Michael ConstantinoIndividual16,000US$0.48
18 May 22BuyUS$50,000Mark SirgoIndividual106,383US$0.47
18 May 22BuyUS$22,285John TemperatoIndividual50,000US$0.45
03 Mar 22BuyUS$55,590John TemperatoIndividual100,000US$0.56
03 Mar 22BuyUS$50,002Mark SirgoIndividual86,449.55US$0.58
02 Dec 21BuyUS$44,500Mark SirgoIndividual50,000US$0.89
18 Nov 21BuyUS$52,500John TemperatoIndividual50,000US$1.05
18 Nov 21BuyUS$21,200Mark SirgoIndividual20,000US$1.06

Ownership Breakdown

What is the ownership structure of NMTR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,186,6881.2%
Hedge Funds14,295,6275.5%
General Public200,490,61277.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 21.7% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Adage Capital Management, L.P.
The Vanguard Group, Inc.
11,502,229$2.7m-1.67%no data
OrbiMed Advisors LLC
Laurion Capital Management LP
BlackRock, Inc.
3,370,798$792.1k-75.91%no data
Geode Capital Management, LLC
2,312,696$543.5k-39.23%no data
Sharpvue Capital, LLC
Millennium Management LLC
1,850,825$434.9k0%no data
Ghost Tree Capital, LLC
Mark Sirgo
1,581,913$371.7k12.44%no data
John Temperato
1,427,522$335.5k9.6%no data
Ergoteles LLC
O'Donnell Financial Services, LLC
State Street Global Advisors, Inc.
806,171$189.5k-78.95%no data
Renaissance Technologies LLC
469,300$110.3k-79.12%no data
GSA Capital Partners LLP
Northern Trust Global Investments
450,126$105.8k-78.12%no data
Wilcoxson Wealth Management
290,402$68.2k38.02%no data
Qube Research And Technologies Ltd
287,807$67.6k0%no data
Adviser Investments, LLC
286,248$67.3k23.98%no data
Group One Trading LP, Asset Management Arm
207,177$48.7k217.81%no data
Valeo Financial Advisors, LLC
198,148$46.6k0%no data
Y-Intercept (Hong Kong) Limited
Virtu Financial LLC, Asset Management Arm
181,983$42.8k0%no data
Susquehanna International Group, LLP, Asset Management Arm
176,659$41.5k40.03%no data

Company Information

9 Meters Biopharma, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: 9 Meters Biopharma, Inc.
  • Ticker: NMTR
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$60.890m
  • Shares outstanding: 259.11m
  • Website:

Number of Employees


  • 9 Meters Biopharma, Inc.
  • 8480 Honeycutt Road
  • Suite 120
  • Raleigh
  • North Carolina
  • 27615
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NMTRNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2018
2Q3DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2018

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/04 00:00
End of Day Share Price2022/10/04 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.